Xilio Therapeutics, Inc. is a clinical-stage biotherapeutics company focused on discovering and developing tumor-selective immuno-oncology therapies. The company has collaboration agreements with AbbVie Group Holdings Limited and a license agreement with Gilead Sciences, Inc. Xilio is developing product candidates aimed at treating cancer, with research programs spanning preclinical studies and clinical trials. The company operates as an emerging growth company under the JOBS Act.
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001193125-26-118550 | EDGAR | 120K words |
| 2025-03-11 | 2024-12-31 | 0001558370-25-002640 | EDGAR | 115K words |
| 2024-04-01 | 2023-12-31 | 0001558370-24-004530 | EDGAR | 113K words |
| 2023-03-02 | 2022-12-31 | 0001558370-23-002687 | EDGAR | 111K words |
| 2022-03-01 | 2021-12-31 | 0001558370-22-002552 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-12 | 2026-06-30 | 0001193125-26-345759 | EDGAR | 80K words |
| 2025-11-13 | 2025-09-30 | 0001193125-25-278837 | EDGAR | 81K words |
| 2025-08-14 | 2025-06-30 | 0001558370-25-011477 | EDGAR | 80K words |
| 2025-05-08 | 2025-03-31 | 0001558370-25-006996 | EDGAR | 75K words |
| 2024-11-07 | 2024-09-30 | 0001558370-24-014775 | EDGAR | 74K words |
| 2024-08-08 | 2024-06-30 | 0001558370-24-011471 | EDGAR | 74K words |
| 2024-05-14 | 2024-03-31 | 0001558370-24-008068 | EDGAR | 72K words |
| 2023-11-09 | 2023-09-30 | 0001558370-23-018587 | EDGAR | 67K words |
| 2023-08-14 | 2023-06-30 | 0001558370-23-014711 | EDGAR | 65K words |
| 2023-05-09 | 2023-03-31 | 0001558370-23-008676 | EDGAR | 63K words |
| 2022-11-09 | 2022-09-30 | 0001558370-22-017018 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001558370-22-012756 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-12 | 0001193125-26-345753 | EDGAR | 3K words |
| 2026-03-23 | 0001193125-26-118544 | EDGAR | 3K words |
| 2026-03-12 | 0001193125-26-103150 | EDGAR | 1K words |
| 2026-03-09 | 0001193125-26-097603 | EDGAR | 5K words |
| 2026-02-24 | 0001193125-26-065234 | EDGAR | 1K words |
| 2026-02-12 | 0001193125-26-048942 | EDGAR | 1K words |
| 2026-01-08 | 0001193125-26-007063 | EDGAR | 2K words |
| 2026-01-05 | 0001193125-26-001580 | EDGAR | 1K words |
| 2025-11-25 | 0001193125-25-297165 | EDGAR | 1K words |
| 2025-11-13 | 0001193125-25-278835 | EDGAR | 4K words |
103 total filings indexed. 76 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001840233 |
| Ticker | XLO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.xiliotx.com |
| Listed | 2021-10-22 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/XLO (~200 tokens, structured JSON with cryptographic provenance)